Assessment

atezolizumab

First-line treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 ≥ 50% of tumour cells (TC) or ≥ 10% of tumour-infiltrating immune cells (IC) and who have no EGFR mutations or ALK-positive NSCLC